ProJenX: protecting neurons to treat ALS

Launched by Project ALS  to develop a neuroprotective molecule for ALS, ProJenX plans to take advantage of the regulatory path recently blazed by Amylyx’s product Relyvrio. 

ProJenX Inc. CEO Stan Abel told BioCentury the company’s lead asset, prosetin, “is one of the first ALS treatments designed, synthesized and optimized with ALS biology and motor neuron survival in mind.” ...